SciBase Holding AB reports Q3 net sales of SEK 10.3 million and loss after tax of SEK 18.8 million
SciBase Holding AB reported net sales of SEK 10.3 million for the third quarter of 2025, an increase of 23% compared to SEK 8.4 million in the same period of 2024. The loss after tax was SEK 18.8 million, compared to a loss of SEK 17.8 million in the previous year. Loss per share for the quarter was SEK 0.05, down from SEK 0.08. The gross margin was 60.0%, compared to 75.7% in the previous year. Electrode sales volume rose by 24% to 21,278 units, with repeat sales to existing customers increasing by 33%. For the first nine months of 2025, net sales reached SEK 28.0 million, up 33% from SEK 21.1 million in 2024, and the gross margin was 65.3%. Cash flow from current operations was negative at SEK 17.3 million for the quarter. After the end of the period, SciBase expanded its collaboration and license agreement with Castle Biosciences, entered into a loan agreement, and the Board resolved on a rights issue of approximately SEK 83 million and an offer to convert outstanding TO2 warrants into shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.